We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
-4.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$44.1B
AUM Growth
+$629M
(+1.4%)
Cap. Flow
+$2.39B
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
11.51%
Holding
3,945
New
199
Increased
895
Reduced
1,260
Closed
190
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halliburton
HAL
|
+$500M |
| 2 |
Archer Daniels Midland
ADM
|
+$463M |
| 3 |
Hewlett Packard
HPE
|
+$425M |
| 4 |
Gen Digital
GEN
|
+$379M |
| 5 |
WCC
WESCO International
WCC
|
+$269M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vistra
VST
|
+$598M |
| 2 |
ExxonMobil
XOM
|
+$504M |
| 3 |
Chevron
CVX
|
+$443M |
| 4 |
Occidental Petroleum
OXY
|
+$439M |
| 5 |
Cummins
CMI
|
+$414M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.1% |
| 2 | Technology | 16.69% |
| 3 | Energy | 13.9% |
| 4 | Industrials | 11.2% |
| 5 | Healthcare | 9.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1351
Qiagen
QGEN
$8.53B
| $12.4K | ﹤0.01% |
294
+35
| +14% | +$1.53K |
|
|
BASE
1352
DELISTED
Couchbase
BASE
| $11.8K | ﹤0.01% |
+646
| New | +$15K |
|
|
DAWN
1353
DELISTED
Day One Biopharmaceuticals
DAWN
| $11.7K | ﹤0.01% |
851
-51
| -6% | -$746 |
|
1354
iShares MSCI Taiwan ETF
EWT
$10B
| $11.5K | ﹤0.01% |
212
+4
| +2% | +$200 |
|
1355
4D Molecular Therapeutics
FDMT
$526M
| $11.4K | ﹤0.01% |
544
-185
| -25% | -$4.64K |
|
1356
Prothena Corp
PRTA
$458M
| $11.4K | ﹤0.01% |
552
-858
| -61% | -$18.6K |
|
1357
InMode
INMD
$872M
| $11.3K | ﹤0.01% |
620
-30
| -5% | -$551 |
|
1358
Unity
U
$12.5B
| $11.1K | ﹤0.01% |
682
+214
| +46% | +$4.58K |
|
1359
Arcturus Therapeutics
ARCT
$157M
| $10.8K | ﹤0.01% |
444
-287
| -39% | -$8.7K |
|
1360
Rush Street Interactive
RSI
$3.24B
| $10.8K | ﹤0.01% |
1,123
-496
| -31% | -$3.97K |
|
1361
Viridian Therapeutics
VRDN
$2.13B
| $10.7K | ﹤0.01% |
825
-1,075
| -57% | -$14.9K |
|
1362
iShares MSCI UAE ETF
UAE
$306M
| $10.7K | ﹤0.01% |
779
+392
| +101% | +$5.57K |
|
1363
Sana Biotechnology
SANA
$885M
| $10.6K | ﹤0.01% |
1,936
-373
| -16% | -$2.97K |
|
1364
MannKind Corp
MNKD
$1.28B
| $10.4K | ﹤0.01% |
1,993
-1,415
| -42% | -$6.42K |
|
1365
Cullinan Oncology
CGEM
$1.05B
| $10.4K | ﹤0.01% |
595
+145
| +32% | +$3.09K |
|
|
EVRI
1366
DELISTED
Everi Holdings
EVRI
| $10.3K | ﹤0.01% |
1,227
+96
| +8% | +$784 |
|
1367
Xencor
XNCR
$1.44B
| $10.3K | ﹤0.01% |
543
-521
| -49% | -$11.2K |
|
1368
SGHC Ltd
SGHC
$7.3B
| $10.2K | ﹤0.01% |
3,146
+495
| +19% | +$1.67K |
|
1369
Praxis Precision Medicines
PRAX
$9.07B
| $9.72K | ﹤0.01% |
+235
| New | +$11.1K |
|
1370
CG Oncology
CGON
$6.11B
| $9.15K | ﹤0.01% |
+290
| New | +$10.1K |
|
1371
Vir Biotechnology
VIR
$1.47B
| $9.15K | ﹤0.01% |
1,028
-1,175
| -53% | -$11.3K |
|
1372
Spyre Therapeutics
SYRE
$8.87B
| $8.98K | ﹤0.01% |
+382
| New | +$12.9K |
|
1373
Cogent Biosciences
COGT
$6.79B
| $8.82K | ﹤0.01% |
1,046
-2,233
| -68% | -$16.9K |
|
1374
Bally's
BALY
$672M
| $8.73K | ﹤0.01% |
729
-85
| -10% | -$1.09K |
|
1375
Travere Therapeutics
TVTX
$5.33B
| $8.52K | ﹤0.01% |
1,037
-1,734
| -63% | -$11.7K |
|
Similar funds
SAM
Pacer Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, Pacer Advisors held 3,945 positions worth $44.1B, up 1.4% from $43.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $2.39B of net new capital in Q2 2024, opening 199 new positions and adding to 895 existing holdings. Its largest new stake was Academy Sports + Outdoors: 3,268,629 shares worth $174M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 17% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Vistra, an estimated $598M trimmed.
- Pacer Advisors's largest Q2 2024 buy was Academy Sports + Outdoors: 3,268,629 shares worth $174M.
- Pacer Advisors added most to Halliburton in Q2 2024, an estimated $500M increase.
- Pacer Advisors's biggest Q2 2024 reduction was Vistra, cutting an estimated $598M.
- Pacer Advisors fully exited American Eagle Outfitters in Q2 2024, selling an estimated $218M.
- Pacer Advisors's ten largest holdings make up 12% of its $44.1B portfolio in Q2 2024.
- Pacer Advisors opened 199 new positions and closed 190 in Q2 2024.
- Pacer Advisors's portfolio value rose 1.4% quarter-over-quarter to $44.1B.
Based on Pacer Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.